In vitro and in vivo experimental activities of antifungal agents against Fusarium solani

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 5, 1999, Pages 1256-1257

  Guarro, J ^a,d   Pujol, I ^b   Mayayo, E ^c  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^c HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^d FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCYTOSINE; RIFAMPICIN;

ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FUSARIUM SOLANI; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032960640     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.5.1256     Document Type: Article

References (13)

1. Anaissie, E., H. Kantarajan, J. Ro, R. Hopfer, K. Rolston, V. Fainstein, and G. Bodey. 1988. The emerging role of Fusarium infections in patients with cancer. Medicine 67:77-83.
2. Anaissie, E. J., R. Hachem, C. Legrand, P. Legenne, P. Nelson, and G. P. Bodey. 1992. Lack of activity of amphotericin B in systemic murine fusarial infection. J. Infect. Dis. 165:1155-1157.
3. Berenbaum, M. D. 1978. A method for testing for synergy with any number of agents. J. Infect. Dis. 137:122-130.
4. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308-329.
5. Guarro, J., and J. Gené. 1995. Opportunistic fusarial infections in humans. Eur. J. Clin. Microbiol. Infect. Dis. 14:741-754.
6. Hoeprich, P. D. 1992. Clinical use of amphotericin B and derivatives: lore, mystique, and fact. Clin. Infect. Dis. 14(Suppl. 1):S114-S119.
7. Nguyen, M. H., F. Barchiesi, D. A. McGough, V. L. Yu, and M. G. Rinaldi. 1995. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob. Agents Chemother. 39:1691-1695.
8. Odds, F. C., F. Van Gerven, A. Espinel-Ingroff, M. S. Bartlett, M. A. Ghannoum, M. V. Lancaster, M. A. Pfaller, J. H. Rex, M. G. Rinaldi, and T. J. Walsh. 1998. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob. Agents Chemother. 42:282-288.
9. Pujol, I., J. Guarro, J. Gené, and J. Sala. 1997. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J. Antimicrob. Chemother. 39:163-167.
10. Reuben, A., E. Anaissie, P. E. Nelson, R. Hashem, C. Legrand, D. H. Ho, and G. P. Bodey. 1989. Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrob. Agents Chemother. 33:1647-1649.
11. Rotowa, N. A., H. J. Shadomy, and S. Shadomy. 1990. In vitro activities of polyene and imidazole antifungal agents against unusual opportunistic fungal pathogens. Mycoses 33:203-211.
12. Sekhon, A. S., A. A. Padhye, A. K. Garg, H. Ahmad, and N. Moledina. 1994. In vitro sensitivity of medically significant Fusarium species to various antimycotics. Chemotherapy (Basel) 40:239-244.
13. Stern, G. A. 1978. In vitro antibiotic synergism against ocular fungal isolates. Am. J. Ophthalmol. 86:359-367.